Clinical Trial Update: Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) [Phase 2]

View source ↗

Summary

This entry describes a Phase 2 clinical trial evaluating chidamide in combination with the PECM regimen for relapsed or refractory peripheral T-cell lymphoma; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Chidamide (chidamide)
• PECM regimen

Snippet

Sponsor: Sun Yat-sen University | Conditions: Peripheral T-cell Lymphoma | Phase 2 | Status: UNKNOWN